文献速递中枢神经肿瘤放疗放疗物理与技术

18F-DOPA PET引导剂量递增放疗治疗胶质母细胞瘤的2期试验初步结果

Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-03-23

这项前瞻性2期研究纳入75例新诊断胶质母细胞瘤患者,采用18F-DOPA PET引导的剂量递增放疗(51、60、76 Gy/30次)联合同步及辅助替莫唑胺。3级中枢神经系统坏死发生率为13%,贝伐珠单抗可改善症状。

要点

  • 18F-DOPA PET引导剂量递增放疗在胶质母细胞瘤中显示安全性可行
  • MGMT未甲基化患者PFS6达79.5%,中位PFS较历史对照显著延长
  • MGMT甲基化患者中位OS显著延长至35.5个月

核心结论

  • 18F-DOPA PET引导的剂量递增放疗似乎安全,显著改善MGMT未甲基化胶质母细胞瘤患者的无进展生存期,并显著改善MGMT甲基化患者的总生存期。

研究设计与样本

  • 前瞻性2期研究,2014年1月至2018年12月纳入75例可评估的新诊断、组织学确诊的胶质母细胞瘤患者(≥18岁),其中MGMT未甲基化39例、甲基化24例、不确定12例。
  • 靶区剂量为51、60、76 Gy分30次同步整合加量,联合同步及辅助替莫唑胺6个月,以18F-DOPA PET引导剂量递增放疗。
  • 研究设计为在MGMT未甲基化患者中检测6个月无进展生存率≥72.5%,总体显著性水平α=0.20、把握度80%;历史对照包括139例(82例未甲基化)在本机构前瞻性临床试验或标准放疗的患者。

主要发现

  • 3级中枢神经系统坏死发生率为13%,贝伐珠单抗治疗在所有病例中改善症状。

关键数值与推荐

  • 靶区剂量:51、60、76 Gy分30次同步整合加量。
  • MGMT未甲基化患者PFS6目标阈值≥72.5%,实际观察79.5%(95%CI 63.1%-90.1%)。
  • 毒性评价采用CTCAE v4.0,3级中枢神经系统坏死13%。

临床怎么用

  • 对MGMT未甲基化胶质母细胞瘤患者,可考虑18F-DOPA PET引导的剂量递增放疗以延长无进展生存期。
  • 对MGMT甲基化患者,该策略可能带来总生存获益。
  • 需警惕3级中枢神经系统坏死,贝伐珠单抗可用于症状改善。

局限性

  • 为2期单臂研究,疗效比较基于历史对照而非随机对照。
  • 样本量有限(75例可评估),MGMT不确定患者12例纳入分析。
  • 随访与长期毒性数据未在摘要中完整报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our previous work demonstrated that 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) positron emission tomography (PET) is sensitive and specific for identifying regions of high density and biologically aggressive glioblastoma. The purpose of this prospective phase 2 study was to determine the safety and efficacy of biologic-guided, dose-escalated radiation therapy (DERT) using 18F-DOPA PET in patients with glioblastoma. METHODS AND MATERIALS: Patients with newly diagnosed, histologically confirmed glioblastoma aged ≥18 years without contraindications to 18F-DOPA were eligible. Target volumes included 51, 60, and 76 Gy in 30 fractions with a simultaneous integrated boost, and concurrent and adjuvant temozolomide for 6 months. 18F-DOPA PET imaging was used to guide DERT. The study was designed to detect a true progression-free survival (PFS) at 6 months (PFS6) rate ≥72.5% in O6-methylguanine methyltransferase (MGMT) unmethylated patients (DE-Un), with an overall significance level (alpha) of 0.20 and a power of 80%. Kaplan-Meier analysis was performed for PFS and overall survival (OS). Historical controls (HCs) included 139 patients (82 unmethylated) treated on prospective clinical trials or with standard RT at our institution. Toxicities were evaluated with Common Terminology Criteria for Adverse Events v4.0. RESULTS: Between January 2014 and December 2018, 75 evaluable patients were enrolled (39 DE-Un, 24 methylated [DE-Mth], and 12 indeterminate). PFS6 for DE-Un was 79.5% (95% confidence interval, 63.1%-90.1%). Median PFS was longer for DE-Un patients compared with historical controls (8.7 months vs 6.6 months; P = .017). OS was similarly longer, but the difference was not significant (16.0 vs 13.5 months; P = .13). OS was significantly improved for DE-Mth patients compared with HC-Mth (35.5 vs 23.3 months; P = .049) despite nonsignificant improvement in PFS (10.7 vs 9.0 months; P = .26). Grade 3 central nervous system necrosis occurred in 13% of patients, but treatment with bevacizumab improved symptoms in all cases. CONCLUSIONS: 18F-DOPA PET-guided DERT appears to be safe, and it significantly improves PFS in MGMT unmethylated glioblastoma. OS is significantly improved in MGMT methylated patients. Further investigation of 18F-DOPA PET biologic guided DERT for glioblastoma is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Laack NN, Pafundi D, Anderson SK, et al. Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. Int J Radiat Oncol Biol Phys. 2021. PMID: 33771703. doi:10.1016/j.ijrobp.2021.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。